This article has been updated to include Illumina's recorded gain on the sale.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has coordinated the acquisition of Illumina's 13.5 percent stake in the company on behalf of certain shareholders.

The unnamed investors acquired Illumina's shares for £56.4 million ($90.7 million), and Illumina said in a regulatory filing Friday that it has recorded a $55.2 million gain from the sale of its stake in Oxford Nanopore.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.